Engineered Soluble ACE2 Protein and SARS-CoV-2 Variants of Concern (VOCs)
Coronaviruses
; 3(5) (no pagination), 2022.
Article
in English
| EMBASE | ID: covidwho-2268502
Keywords
covid-19, Engineered soluble ACE2 protein, epidemic illnesses, SARS-CoV-2, trimeric S protein, variants of concern, acute lung injury, adult respiratory distress syndrome, coronavirus disease 2019, cytokine storm, editorial, epidemic, exosome, fibrosis, human, ic50, in vitro study, in vivo study, innate immunity, pandemic, public health, pyroptosis, receptor binding, renin angiotensin aldosterone system, SARS-CoV-2 (lineage B.1), SARS-CoV-2 (variant B.1.1.7 UK/Alpha/mutant 69-70del), SARS-CoV-2 (variant B.1.351 RSA/Beta/mutant D614G), SARS-CoV-2 (variant B.1.617.2/Delta/India/mutant D614G; D950N), SARS-CoV-2 Gamma, Severe acute respiratory syndrome coronavirus 2, socioeconomics, trimerization, vaccination, vaccine development, variant of concern, vasodilatation, virus entry, virus shedding, virus spike, ADAM protein/ec [Endogenous Compound], angiotensin 2 receptor antagonist, angiotensin converting enzyme 2/ec [Endogenous Compound], angiotensin I/ec [Endogenous Compound], angiotensin II/ec [Endogenous Compound], angiotensin[1-7]/ec [Endogenous Compound], immunoglobulin G/ec [Endogenous Compound], monoclonal antibody/ec [Endogenous Compound], reactive oxygen metabolite, unclassified drug, vitronectin, angiotensin[1-9]/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Variants
Language:
English
Journal:
Coronaviruses
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS